As a company, we are more committed to produce quality products and the focus will always remain the same. We are well known for our best and dedicated customer services with all our customers. We are always focused on making sure that needy patients get their medicines in time by putting special emphasis on the planning and supply chain.
In regards to the people we work with we serve all the mainlines, multiple retailers and wholesalers, supermarkets and we also supply NHS contracts.
The generic market at present in the UK is very competitive and challenging. Investing in new products especially niche products is the key for future growth. My focus has always been to reinvest into new product development and I am glad we have a good pipeline of new products which can catalyse the future growth.
Before joining RelonChem, I completed my master degree in Pharmaceutical Sciences and have gone on to acquire more than 17 years’ experience in the pharmaceutical industry. I have worked in pharmaceutical manufacturing, formulation development, regulatory affairs, commercial and sales before I became Managing Director of this company.
I am both surprised and truly honoured to have won this award. I would like to thank all of my colleagues who made this possible. Winning this award gives me a sense of recognition and further encourages me to achieve more and more.
Looking ahead to the future we will be looking to launch number of new products and also identify more products for development so that the community can benefit from quality and affordable medicines. We will also be looking to enter in to the new dosage forms either by acquiring new licenses or by developing new products.
Arguably the biggest challenge for both myself and the company will be sustain the current growth and grow further from there making sure all the targeted new products are launched in time. Increased competition, new players, volatility in pricing and the increased compliance costs will continue to be the challenges in the pharmaceutical industry.